<DOC>
	<DOCNO>NCT00134498</DOCNO>
	<brief_summary>The Torcetrapib project terminate December 2 , 2006 due safety finding . To assess safety efficacy fix combination torcetrapib/atorvastatin subject Fredrickson Type IV Hypertriglyceridemia .</brief_summary>
	<brief_title>A Study Comparing The Efficacy &amp; Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides</brief_title>
	<detailed_description>For additional information please call : 1-800-718-1021</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type IV</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis Fredrickson Type IV Hypertriglyceridemia Women pregnant lactating , plan become pregnant . Subjects clinically indicate need statin ( HMGCoA reductase inhibitor ) therapy atorvastatin concomitant therapy know lipid alter effect LDLC HDLC include fibrates nicotinic acid Subjects take drug know associate increase risk myositis combination HMGCoA reductase inhibitor Subjects medical condition laboratory abnormality could affect subject safety , preclude evaluation response , render unlikely subject would complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>